262 related articles for article (PubMed ID: 28594314)
1. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
Tan-Koi WC; Sung C; Chong YY; Lateef A; Pang SM; Vasudevan A; Aw D; Lui NL; Lee SX; Ren EC; Koay ES; Tay YK; Lim YL; Lee HY; Dong D; Loke C; Tan L; Limenta M; Lee EJ; Toh D; Chan CL
Pharmacogenomics; 2017 Jun; 18(9):881-890. PubMed ID: 28594314
[TBL] [Abstract][Full Text] [Related]
2. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study.
Toh DS; Tan LL; Aw DC; Pang SM; Lim SH; Thirumoorthy T; Lee HY; Tay YK; Tan SK; Vasudevan A; Lateef A; Chong YY; Chan YC; Loke C; Chan CL; Koay ES; Ren EC; Lee EJ; Sung C
Pharmacogenomics J; 2014 Aug; 14(4):316-21. PubMed ID: 24394201
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of allopurinol--making an old drug safer.
Lam MP; Yeung CK; Cheung BM
J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
[TBL] [Abstract][Full Text] [Related]
4. Genetics and the potential for predictive tests in adverse drug reactions.
Pirmohamed M
Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
[TBL] [Abstract][Full Text] [Related]
5. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Kaniwa N; Saito Y
J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
[TBL] [Abstract][Full Text] [Related]
7. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
8. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
9. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.
Jarjour S; Barrette M; Normand V; Rouleau JL; Dubé MP; de Denus S
Pharmacogenomics; 2015; 16(7):755-67. PubMed ID: 25965122
[TBL] [Abstract][Full Text] [Related]
10. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.
Chong KW; Chan DW; Cheung YB; Ching LK; Hie SL; Thomas T; Ling S; Tan EC
Arch Dis Child; 2014 Jun; 99(6):581-4. PubMed ID: 24225276
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.
Daly AK
Curr Drug Metab; 2014 Feb; 15(2):196-201. PubMed ID: 24694233
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of severe cutaneous adverse reactions.
Kaniwa N; Saito Y
Pharmacogenomics; 2013 Apr; 14(6):595-8. PubMed ID: 23570461
[No Abstract] [Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Phillips EJ; Sukasem C; Whirl-Carrillo M; Müller DJ; Dunnenberger HM; Chantratita W; Goldspiel B; Chen YT; Carleton BC; George AL; Mushiroda T; Klein T; Gammal RS; Pirmohamed M
Clin Pharmacol Ther; 2018 Apr; 103(4):574-581. PubMed ID: 29392710
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
15. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.
Rufini S; Ciccacci C; Politi C; Giardina E; Novelli G; Borgiani P
Pharmacogenomics; 2015 Nov; 16(17):1989-2002. PubMed ID: 26555663
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
[TBL] [Abstract][Full Text] [Related]
17. Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.
Cheng L; Zhang L; Gao L; Zhang W; Chen X; Zhou HH
Clin Transl Sci; 2015 Dec; 8(6):834-6. PubMed ID: 26663557
[TBL] [Abstract][Full Text] [Related]
18. An update on HLA alleles associated with adverse drug reactions.
Fricke-Galindo I; LLerena A; López-López M
Drug Metab Pers Ther; 2017 May; 32(2):73-87. PubMed ID: 28315856
[TBL] [Abstract][Full Text] [Related]
19. [The associations between idiosyncratic adverse drug reactions and HLA alleles and their underlying mechanism].
Wang Q; Mei H; Zhang YL; Pan XC; Tan W; Chao L
Yao Xue Xue Bao; 2013 Jun; 48(6):799-808. PubMed ID: 23984511
[TBL] [Abstract][Full Text] [Related]
20. Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR.
Zhang X; Ma H; Hu C; Yu B; Ma W; Wu Z; Luo X; Zou H; Guan M
Clin Chem Lab Med; 2015 Feb; 53(3):383-90. PubMed ID: 25257159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
